Streetbeat News

Analyst Ratings

AAWH

ACRHF

CRLBF

CURLF

GTBIF

TCNNF

VRNOF

Senior analyst Pablo Zuanic from Zuanic & Associates has provided a valuation assessment of US Multi-State Operators (MSOs) in the cannabis sector, considering potential federal regulatory changes and state-level legalization trends. He uses a comprehensive methodology to calculate enterprise values (EV) for MSOs, including Acreage Holdings, Ascend Wellness, Curaleaf, Green Thumb Industries, Trulieve, Cresco Labs, and Verano. The analysis is based on factors such as share counts, net debt, and contingent liabilities. The US legal cannabis market is expected to grow significantly, from $18 million in CY20 to $40 million in CY27, indicating a positive outlook for MSOs.

Portfolio Pulse from Nicolás Jose Rodriguez

November 17, 2023 | 4:01 pm

HRMY

Zacks Home Run Investor Newsletter has reportedly picked Harmony Biosciences (HRMY) as a stock to watch, which could influence investor interest and trading activity in the company's shares.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 4:01 pm

FMC

UBS analyst Joshua Spector has maintained a Neutral rating on FMC Corporation (NYSE:FMC) and reduced the price target from $64 to $59.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 4:00 pm

DGX

Over the last quarter, Quest Diagnostics (NYSE:DGX) received 4 indifferent analyst ratings with no bullish or bearish positions. The average 12-month price target for DGX is $137.25, with a high of $149.00 and a low of $130.00. This target has decreased by 2.83% from the previous target of $141.25. Analyst ratings are provided quarterly and are based on financial analysis and insider information, but they are subject to human error.

Portfolio Pulse from Benzinga Insights

November 17, 2023 | 4:00 pm

ARCH

Arch Resources (NYSE:ARCH) has received 5 analyst ratings in the last quarter, with 3 being bullish and 2 somewhat bullish. There have been no indifferent, somewhat bearish, or bearish ratings. The average 12-month price target among these analysts is $182.00, with a high of $197.00 and a low of $170.00. This target has decreased by 1.22% from the previous target of $184.25. Analyst ratings are based on predictions of a company's future earnings and revenue, and are updated quarterly or after major company events.

Portfolio Pulse from Benzinga Insights

November 17, 2023 | 4:00 pm

LH

7 Wall Street analysts have provided ratings for Laboratory Corp (NYSE:LH) over the past 3 months, with an average 12-month price target of $242.14, a decrease from the previous target of $251.25. The ratings include 4 bullish, 2 somewhat bullish, and 1 indifferent. No bearish ratings were reported. The high price target is $270.00 and the low is $210.00.

Portfolio Pulse from Benzinga Insights

November 17, 2023 | 4:00 pm

ELV

Elevance Health (NYSE:ELV) received four somewhat bullish analyst ratings in the last quarter, with no bearish or indifferent ratings. The average 12-month price target for ELV is $558.25, which is a 3.25% decrease from the previous target of $577.00. Analysts provide ratings based on financial statements, meetings, and insider information, and these ratings are updated quarterly.

Portfolio Pulse from Benzinga Insights

November 17, 2023 | 4:00 pm

SQM

Analysts have recently provided ratings for Sociedad Quimica Y Minera (NYSE:SQM), with 1 bullish, 3 somewhat bullish, 2 indifferent, and 1 somewhat bearish rating over the last quarter. The average price target is $76.14, which is significantly higher than the current price of $47.92, suggesting an implied upside. However, this target represents a 10.95% decrease from the previous target of $85.50.

Portfolio Pulse from Benzinga Insights

November 17, 2023 | 4:00 pm

HCA

JP Morgan analyst Samik Chatterjee has maintained a Neutral rating on HCA Healthcare (NYSE:HCA) but has reduced the price target from $313 to $265.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 4:00 pm

DVA

UBS analyst Andrew Mok has maintained a Buy rating on DaVita (NYSE:DVA) but has reduced the price target from $142 to $113.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 3:58 pm